GlaxoSmithKline saw its share price fall 6% yesterday after releasing underwhelming figures in Q3, and leaving investors uncertain about its future dividend payments.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.